Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.

Kiss, Szilárd; Liu, Ying; Brown, Joseph; Holekamp, Nancy M; Almony, Arghavan; Campbell, Joanna; Kowalski, Jonathan W

Kiss, Szilárd; Liu, Ying; Brown, Joseph; Holekamp, Nancy M; Almony, Arghavan; Campbell, Joanna; Kowalski, Jonathan W.

Afiliación

Kiss S; Weill Cornell Medical College, New York, NY, USA.
Liu Y; Allergan, Inc., Irvine, CA, USA.
Brown J; IMS Health, Woodland Hills, CA, USA.
Holekamp NM; Pepose Vision Institute, Chesterfield, MO, USA ; Washington University School of Medicine, St Louis, MO, USA.
Almony A; Carolina Eye Associates, Southern Pines, NC, USA.
Campbell J; Allergan, Inc., Irvine, CA, USA.
Kowalski JW; Allergan, Inc., Irvine, CA, USA.

Clin Ophthalmol ; 8: 1611-21, 2014.

Article en En | MEDLINE | ID: mdl-25210429

Palabras clave

anti-vascular endothelial growth factor; bevacizumab; diabetic macular edema; intravitreal; ranibizumab; retinal vein occlusion

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Ophthalmol Año: 2014 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google